Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5728

1.

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients with Ulcerative Colitis.

Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C.

Clin Gastroenterol Hepatol. 2018 Jul 13. pii: S1542-3565(18)30709-2. doi: 10.1016/j.cgh.2018.07.009. [Epub ahead of print]

PMID:
30012431
2.

Cyclosporine.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

3.

Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.

Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F.

Inflamm Bowel Dis. 2018 Jul 6. doi: 10.1093/ibd/izy229. [Epub ahead of print]

PMID:
29982631
4.

Anxiety, depression, and inflammation after restorative proctocolectomy.

Gorrepati VS, Yadav S, Stuart A, Koltun W, Messaris E, Williams ED, Coates MD.

Int J Colorectal Dis. 2018 Jun 29. doi: 10.1007/s00384-018-3110-y. [Epub ahead of print]

PMID:
29959529
5.

Ulcerative colitis with Guillain-Barré syndrome: A case report.

Liu Z, Zhou K, Tian S, Dong W.

Medicine (Baltimore). 2018 Jun;97(25):e11013. doi: 10.1097/MD.0000000000011013.

6.

Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.

Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C.

J Crohns Colitis. 2018 Jun 18. doi: 10.1093/ecco-jcc/jjy079. [Epub ahead of print]

PMID:
29917070
7.

Contemporary Medical Management of Acute Severe Ulcerative Colitis.

Whaley KG, Rosen MJ.

Inflamm Bowel Dis. 2018 Jun 7. doi: 10.1093/ibd/izy208. [Epub ahead of print]

PMID:
29889235
8.

Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.

O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D.

Eur J Gastroenterol Hepatol. 2018 Jun 6. doi: 10.1097/MEG.0000000000001177. [Epub ahead of print]

PMID:
29878945
9.

Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.

Park KT, Sceats L, Dehghan M, Trickey AW, Wren A, Wong JJ, Bensen R, Limketkai BN, Keyashian K, Kin C.

Aliment Pharmacol Ther. 2018 Aug;48(3):340-346. doi: 10.1111/apt.14842. Epub 2018 Jun 7.

PMID:
29876995
10.

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr.

J Gastroenterol. 2018 Jun 4. doi: 10.1007/s00535-018-1480-0. [Epub ahead of print]

PMID:
29869016
11.

Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.

Gherardi A, Roze S, Kuijvenhoven J, Ghatnekar O, Yip Sonderegger YL.

J Med Econ. 2018 Jun 22:1-9. doi: 10.1080/13696998.2018.1484371. [Epub ahead of print]

PMID:
29857775
12.

Increased Risk of Herpes Zoster Infection in Patients With Inflammatory Bowel Diseases in Korea.

Chang K, Lee HS, Kim YJ, Kim SO, Kim SH, Lee SH, Song EM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK.

Clin Gastroenterol Hepatol. 2018 May 29. pii: S1542-3565(18)30556-1. doi: 10.1016/j.cgh.2018.05.024. [Epub ahead of print]

PMID:
29857150
13.

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn's Disease.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C.

Gastroenterology. 2018 May 29. pii: S0016-5085(18)34572-4. doi: 10.1053/j.gastro.2018.05.039. [Epub ahead of print]

PMID:
29857091
14.

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.

Inflamm Bowel Dis. 2018 May 18. doi: 10.1093/ibd/izy155. [Epub ahead of print]

PMID:
29788318
15.

Correction: Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort.

Waljee AK, Wiitala WL, Govani S, Stidham R, Saini S, Hou J, Feagins LA, Khan N, Good CB, Vijan S, Higgins PDR.

PLoS One. 2018 May 9;13(5):e0197341. doi: 10.1371/journal.pone.0197341. eCollection 2018.

16.

Solitary rectal ulcer syndrome: A systematic review.

Forootan M, Darvishi M.

Medicine (Baltimore). 2018 May;97(18):e0565. doi: 10.1097/MD.0000000000010565. Review.

17.

Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.

Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2018 Jun;47(12):1578-1596. doi: 10.1111/apt.14672. Epub 2018 Apr 25. Review.

PMID:
29696670
18.

The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases.

Kluthe C, Tsui J, Spady D, Carroll M, Wine E, Huynh HQ.

Can J Gastroenterol Hepatol. 2018 Feb 25;2018:4687041. doi: 10.1155/2018/4687041. eCollection 2018.

19.

Risk of Fractures in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A.

J Clin Gastroenterol. 2018 Apr 18. doi: 10.1097/MCG.0000000000001031. [Epub ahead of print]

PMID:
29672437
20.

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR.

Inflamm Bowel Dis. 2018 May 18;24(6):1185-1192. doi: 10.1093/ibd/izy031.

PMID:
29668915

Supplemental Content

Loading ...
Support Center